Editas Medicine Inc., of Cambridge, Mass., a genome editing firm, priced a public offering of 1.97 million shares of common stock for gross proceeds of about $50 million. Underwriters have a 30-day option to purchase up to an additional 295,500 shares. Morgan Stanley is acting as sole book running manager. The share price was not disclosed. Editas' stock (NASDAQ:EDIT) closed Wednesday at $25.18, down $2.12.